Maxim downgrades Inovio, saying coronavirus opportunity is already 'priced in'Market Watch • 07/01/20
Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The SidelinesBenzinga • 07/01/20
This Top Covid-19 Play Just Crumbled On Vague Coronavirus Vaccine DataInvestors Business Daily • 06/30/20
Benchmark analyst expects FDA to allow Inovio's coronavirus vaccine to move to Phase 2/3 clinicalMarket Watch • 06/30/20
Why ‘Positive Results’ in Coronavirus Are Not Good Enough for Inovio Pharma24/7 Wall Street • 06/30/20